ORASURE TECHNOLOGIES INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that ORASURE TECHNOLOGIES INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Dec 31, 2019 | $49.67M | Mar 2, 2020 |
| FY2019 | Sep 30, 2019 | $35.99M | Mar 2, 2020 |
| FY2019 | Jun 30, 2019 | $38.83M | Mar 2, 2020 |
| FY2019 | Mar 31, 2019 | $30.12M | Mar 2, 2020 |
| FY2019 | Dec 31, 2018 | $50.25M | Mar 2, 2020 |
| FY2019 | Sep 30, 2018 | $45.89M | Mar 2, 2020 |
| FY2019 | Jun 30, 2018 | $43.63M | Mar 2, 2020 |
| FY2019 | Mar 31, 2018 | $41.99M | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | $52.03M | Feb 28, 2019 |
| FY2018 | Sep 30, 2017 | $42.31M | Feb 28, 2019 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $115.02M | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | $185.83M | Mar 9, 2026 |
| FY2025 | Dec 31, 2023 | $405.47M | Mar 9, 2026 |
| FY2024 | Dec 31, 2022 | $387.48M | Mar 7, 2025 |
| FY2023 | Dec 31, 2021 | $233.67M | Mar 11, 2024 |
| FY2022 | Dec 31, 2020 | $171.72M | Mar 3, 2023 |
| FY2021 | Dec 31, 2019 | $154.61M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $181.74M | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $167.06M | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | $128.20M | Feb 28, 2019 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $48.20M | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | $79.39M | Mar 9, 2026 |
| FY2025 | Dec 31, 2023 | $171.65M | Mar 9, 2026 |
| FY2024 | Dec 31, 2022 | $148.44M | Mar 7, 2025 |
| FY2023 | Dec 31, 2021 | $117.60M | Mar 11, 2024 |
| FY2022 | Dec 31, 2020 | $101.87M | Mar 3, 2023 |
| FY2021 | Dec 31, 2019 | $94.58M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $113.61M | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $98.96M | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | $88.03M | Feb 28, 2019 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($68.73M) | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | ($19.50M) | Mar 9, 2026 |
| FY2025 | Dec 31, 2023 | $53.66M | Mar 9, 2026 |
| FY2024 | Dec 31, 2022 | ($17.13M) | Mar 7, 2025 |
| FY2023 | Dec 31, 2021 | ($23.00M) | Mar 11, 2024 |
| FY2022 | Dec 31, 2020 | ($14.92M) | Mar 3, 2023 |
| FY2019 | Dec 31, 2019 | $2.44M | Mar 2, 2020 |
| FY2019 | Sep 30, 2019 | $13.08M | Mar 2, 2020 |
| FY2019 | Jun 30, 2019 | $4.40M | Mar 2, 2020 |
| FY2019 | Mar 31, 2019 | ($3.26M) | Mar 2, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($71.97M) | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | ($28.25M) | Mar 9, 2026 |
| FY2025 | Dec 31, 2023 | $32.68M | Mar 9, 2026 |
| FY2024 | Dec 31, 2022 | ($22.16M) | Mar 7, 2025 |
| FY2023 | Dec 31, 2021 | ($10.16M) | Mar 11, 2024 |
| FY2022 | Dec 31, 2020 | ($5.18M) | Mar 3, 2023 |
| FY2019 | Dec 31, 2019 | $4.09M | Mar 2, 2020 |
| FY2019 | Sep 30, 2019 | $13.05M | Mar 2, 2020 |
| FY2019 | Jun 30, 2019 | $5.29M | Mar 2, 2020 |
| FY2019 | Mar 31, 2019 | ($3.81M) | Mar 2, 2020 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $42.53M | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | $26.05M | Mar 9, 2026 |
| FY2025 | Dec 31, 2023 | $33.73M | Mar 9, 2026 |
| FY2024 | Dec 31, 2022 | $36.24M | Mar 7, 2025 |
| FY2023 | Dec 31, 2021 | $34.17M | Mar 11, 2024 |
| FY2022 | Dec 31, 2020 | $31.03M | Mar 3, 2023 |
| FY2021 | Dec 31, 2019 | $19.63M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $16.25M | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $13.37M | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | $9.75M | Feb 28, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($49.02M) | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | $27.37M | Mar 9, 2026 |
| FY2025 | Dec 31, 2023 | $141.58M | Mar 9, 2026 |
| FY2024 | Dec 31, 2022 | ($47.20M) | Mar 7, 2025 |
| FY2023 | Dec 31, 2021 | ($35.38M) | Mar 11, 2024 |
| FY2022 | Dec 31, 2020 | $5.81M | Mar 3, 2023 |
| FY2021 | Dec 31, 2019 | $9.80M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $39.09M | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $28.16M | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | $24.60M | Feb 28, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.20M | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | $3.80M | Mar 9, 2026 |
| FY2025 | Dec 31, 2023 | $5.80M | Mar 9, 2026 |
| FY2024 | Dec 31, 2022 | $6.77M | Mar 7, 2025 |
| FY2023 | Dec 31, 2021 | $21.89M | Mar 11, 2024 |
| FY2022 | Dec 31, 2020 | $26.67M | Mar 3, 2023 |
| FY2021 | Dec 31, 2019 | $9.31M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $6.34M | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $4.34M | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | $4.35M | Feb 28, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $403.17M | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | $479.66M | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | $482.85M | Mar 7, 2025 |
| FY2023 | Dec 31, 2022 | $444.18M | Mar 11, 2024 |
| FY2022 | Dec 31, 2021 | $460.99M | Mar 3, 2023 |
| FY2021 | Dec 31, 2020 | $454.47M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $349.30M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $315.57M | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | $296.20M | Feb 28, 2019 |
| FY2017 | Dec 31, 2016 | $207.94M | Feb 28, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $62.34M | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | $69.32M | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | $52.17M | Mar 7, 2025 |
| FY2023 | Dec 31, 2022 | $79.76M | Mar 11, 2024 |
| FY2022 | Dec 31, 2021 | $80.46M | Mar 3, 2023 |
| FY2021 | Dec 31, 2020 | $55.90M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $42.15M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $32.19M | Mar 2, 2020 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $340.83M | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | $410.34M | Mar 9, 2026 |
| FY2025 | Dec 31, 2023 | $430.67M | Mar 9, 2026 |
| FY2025 | Dec 31, 2022 | $364.43M | Mar 9, 2026 |
| FY2024 | Dec 31, 2021 | $380.53M | Mar 7, 2025 |
| FY2023 | Dec 31, 2020 | $398.57M | Mar 11, 2024 |
| FY2022 | Dec 31, 2019 | $307.15M | Mar 3, 2023 |
| FY2021 | Dec 31, 2018 | $283.38M | Mar 1, 2022 |
| FY2020 | Dec 31, 2017 | $258.08M | Mar 1, 2021 |
| FY2019 | Dec 31, 2016 | $185.85M | Mar 2, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $43.36M | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | $40.33M | Mar 9, 2026 |
| FY2025 | Dec 31, 2023 | $35.70M | Mar 9, 2026 |
| FY2023 | Dec 31, 2022 | $35.10M | Mar 11, 2024 |
| FY2023 | Dec 31, 2021 | $40.28M | Mar 11, 2024 |
| FY2022 | Dec 31, 2020 | $40.35M | Mar 3, 2023 |
| FY2021 | Dec 31, 2019 | $36.20M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $18.52M | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $20.08M | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | $18.79M | Feb 28, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($172.16M) | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | ($103.43M) | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | ($83.93M) | Mar 7, 2025 |
| FY2023 | Dec 31, 2022 | ($137.59M) | Mar 11, 2024 |
| FY2022 | Dec 31, 2021 | ($120.45M) | Mar 3, 2023 |
| FY2021 | Dec 31, 2020 | ($97.46M) | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | ($82.53M) | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | ($99.19M) | Mar 2, 2020 |
| FY2019 | Dec 31, 2017 | ($119.51M) | Mar 2, 2020 |
| FY2017 | Dec 31, 2016 | ($150.46M) | Feb 28, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $199.28M | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | $267.76M | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | $290.41M | Mar 7, 2025 |
| FY2023 | Dec 31, 2022 | $83.98M | Mar 11, 2024 |
| FY2022 | Dec 31, 2021 | $116.76M | Mar 3, 2023 |
| FY2021 | Dec 31, 2020 | $160.80M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $75.72M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $88.44M | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | $71.03M | Feb 28, 2019 |
| FY2017 | Dec 31, 2016 | $107.96M | Feb 28, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 9, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Mar 9, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Mar 7, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Mar 11, 2024 |
| FY2022 | Dec 31, 2020 | 0 | Mar 3, 2023 |
| FY2019 | Dec 31, 2019 | 0 | Mar 2, 2020 |
| FY2019 | Sep 30, 2019 | 0 | Mar 2, 2020 |
| FY2019 | Jun 30, 2019 | 0 | Mar 2, 2020 |
| FY2019 | Mar 31, 2019 | 0 | Mar 2, 2020 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 9, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Mar 9, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Mar 7, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Mar 11, 2024 |
| FY2022 | Dec 31, 2020 | 0 | Mar 3, 2023 |
| FY2019 | Dec 31, 2019 | 0 | Mar 2, 2020 |
| FY2019 | Sep 30, 2019 | 0 | Mar 2, 2020 |
| FY2019 | Jun 30, 2019 | 0 | Mar 2, 2020 |
| FY2019 | Mar 31, 2019 | 0 | Mar 2, 2020 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 70.39M | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | 74.60M | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | 73.53M | Mar 7, 2025 |
| FY2023 | Dec 31, 2022 | 72.73M | Mar 11, 2024 |
| FY2022 | Dec 31, 2021 | 72.07M | Mar 3, 2023 |
| FY2021 | Dec 31, 2020 | 71.74M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | 61.73M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | 61.28M | Mar 2, 2020 |
| FY2018 | Sep 30, 2018 | 61.28M | Feb 28, 2019 |
| FY2018 | Dec 31, 2017 | 60.66M | Feb 28, 2019 |